Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HLA-A2 peptides

Vaccine (Peptide vaccine) · Immune activation, directed at Tyrosinase (TYR), MAGE-C2 and NY-ESO-1 (CTAG1B)

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is HLA-A2 peptides?

HLA-A2 peptides are a set of synthetic peptide vaccine components, each matched to HLA-A2 and derived from a tumor antigen such as tyrosinase, NY-ESO-1 and several MAGE family proteins. They are studied for immune activation against melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
Tyrosinase (TYR) (antigen), MAGE-C2 (antigen), NY-ESO-1 (CTAG1B) (antigen), MAGE-4 (MAGEA4) (antigen), MAGE-3 (MAGEA3) (antigen), MAGE-1 (MAGEA1) (antigen)
Mechanism
Immune activation, directed at Tyrosinase (TYR), MAGE-C2 and NY-ESO-1 (CTAG1B)
Therapy area
Oncology
In trials of
IMMP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00365937 Phase 1/2 Melanoma Terminated IMMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.